



## Financial Tear Sheet

### Corporate Profile

ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Additional clinical trials of Iclusig in other cancers are ongoing. ARIAD is also studying AP26113, another molecularly targeted medicine, in certain forms of lung cancer.


### Primary IR Contact

Manmeet Soni  
Chief Financial Officer  
ARIAD Pharmaceuticals,  
Inc.  
**Phone:**617-503-7298  
**E-mail:**  
manmeet.soni@ariad.com

### Stock Performance

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$23.99
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	0
<b>52 Week Low</b>	\$4.67
<b>Market Cap</b>	\$4,658,878,679
<b>Rolling EPS</b>	-0.18
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	194,200,862

Data as of 02/15/17 4:15 p.m. ET



## Recent Headlines & Events

04/28/17 - 6:53 p.m.

Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib)

02/16/17 - 8:56 a.m.

Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

02/06/17 - 7:35 a.m.

ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

There are currently no events scheduled.

## Analyst Estimates / Ratings

### Mean Recommendation:

Sell                      Strong Buy

### EPS Trend

Current    30 Days Ago    90 Days Ago

QTR

QTR

QTR

QTR

FY

FY

## SEC Filings

Filing Date	Form
04/07/17	SC 13G/A
02/27/17	CT ORDER
02/27/17	15-12B
02/21/17	SC 13D/A

## Corporate Governance

Harvey J. Berger, M.D.	Chairman and Chief Executive Officer
David Berstein, Esq.	Senior Vice President and Chief Intellectual Property Officer
Daniel M. Bollag, Ph.D.	Senior Vice President of Regulatory Affairs and Quality
Joseph Bratica	Vice President, Finance and Controller

Maria E. Cantor	Senior Vice President, Corporate Affairs
Timothy P. Clackson, Ph.D.	President of Research and Development and Chief Scientific Officer
David C. Dalgarno, Ph.D.	Vice President, Research Technologies
Jonathan E. Dickinson	Vice President, European Operations and General Manager, ARIAD Pharmaceuticals (Europe), Sarl
Pierre F. Dodion, M.D., M.B.A	Senior Vice President, Corporate Development and Operations
Martin J. Duvall	Senior Vice President, Commercial Operations
Edward M. Fitzgerald	Executive Vice President, Chief Financial Officer and Treasurer
Frank G. Haluska, M.D., Ph.D.	Chief Medical Officer and Senior Vice President, Clinical R&D
Shirish Hirani, Ph.D.	Vice President, Program and Alliance Management
Stephen R. Jamieson	Vice President, Information Technology
Raymond T. Keane, Esq.	Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Ronald K. Knickerbocker, Ph.D.	Vice President, Biomedical Data Sciences and Information

Jing L. Marantz, M.D., Ph.D.	Vice President, Medical Affairs
Victor M. Rivera, Ph.D.	Vice President, Preclinical and Translational Research
William C. Shakespeare, Ph.D.	Vice President, Drug Discovery

## Ownership Summary

	Holders	Value (\$MM)	% O/S	Shares
Institution	51	198.23	7.2	14,007,670
Mutual Fund	76	184.31	6.4	12,348,828
Insider *	11	22.30	1.9	3,674,626

\*Insider values reflect direct beneficial ownership.

### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Berger (Harvey J)	4,371,103	2.3	0	05/20/16
Norges Bank Investment Management (NBIM)	2,339,750	1.2	673,757	12/31/16
Odey Asset Management LLP	1,991,643	1.0	1,991,643	01/31/17
FNY Partners Fund LP	1,428,547	0.7	1,428,547	03/31/17
LaMarche (Jay R)	549,526	0.3	-9,375	05/20/16
Fitzgerald (Edward M)	320,995	0.2	0	05/20/16
UOB Asset Management Ltd.	252,590	0.1	252,590	12/31/16
Groupama Asset Management	241,659	0.1	-75,076	12/31/16
Alean (Capital) Anstalt	240,000	0.1	240,000	06/30/16
Clackson (Timothy P)	215,855	0.1	19,723	01/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources